TEL AVIV, Israel, June 11, 2025 -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), a clinical stage biotechnology company, announced positive feedback from two recent meetings with the FDA, facilitating the advancement of their drug nebokitug into a Phase 3 clinical trial for Primary Sclerosing Cholangitis $(PSC.AU)$. The FDA has aligned with Chemomab on essential Chemistry, Manufacturing, and Controls $(CMC)$ requirements, ensuring the quality and consistency of the drug supply, and has also agreed to allow non-clinical toxicology studies to proceed concurrently with the Phase 3 clinical trial. This regulatory progress supports the timely advancement of nebokitug's development program as Chemomab continues discussions with potential strategic partners.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.